54 completed, 12 terminated, 11 recruiting, 9 active not recruiting. 99 Phase 1, 41 Phase 2.
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia Ibrutinib, Bendamustine, Rituximab - Waldenström Macroglobulinemia (WM) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2025-09-01 | 2025-09-11 |
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Bendamustine, Biopsy, Biospecimen Collection - Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-15 | 2025-04-01 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 1 | Recruiting | Stanford University | 12 | 2024-04-10 | 2026-02-27 |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease FT819, Fludarabine, Cyclophosphamide - Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 | Recruiting | Fate Therapeutics | 244 | 2024-03-28 | 2026-05-22 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors FT825, Fludarabine, Cyclophosphamide - Advanced Solid Tumor | Phase 1 | Recruiting | Fate Therapeutics | 351 | 2024-01-05 | 2025-12-09 |
| T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer Bendamustine, Biopsy, Biospecimen Collection - Non-small Cell Lung Cancer, Pancreas Cancer | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2023-12-15 | 2026-10-20 |
| FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) FT522, Rituximab, Cyclophosphamide - Relapsed/Refractory B-Cell Lymphoma | Phase 1 | Completed | Fate Therapeutics | 20 | 2023-11-16 | 2025-08-22 |
| Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients Atezolizumab, BEGEV - Relapsed or Refractory Hodgkin's Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Fondazione Italiana Linfomi - ETS | 122 | 2023-02-27 | 2026-09-11 |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Bendamustine, Rituximab, Tazemetostat - Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Vaishalee Kenkre | 42 | 2023-01-26 | 2026-02-17 |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma FT596, Cyclophosphamide, Doxorubicin - Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma | Phase 1 | Withdrawn | Fate Therapeutics | 2022-12-01 | 2023-07-06 | |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy Nivolumab, Autologous CD30.CAR-T, Fludarabine - Classical Hodgkin Lymphoma, Hodgkin Disease Refractory | Phase 1 | Active not recruiting | Tessa Therapeutics | 15 | 2022-07-25 | 2023-04-03 |
| Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 9 | 2021-12-14 | 2026-07-02 |
| FT576 in Subjects With Multiple Myeloma FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine - Multiple Myeloma, Myeloma | Phase 1 | Completed | Fate Therapeutics | 31 | 2021-11-10 | 2025-12-12 |
| Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma CC-220, Polatuzumab vedotin, Rituximab - Lymphoma, B-Cell | Phase 1 / Phase 2 | Withdrawn | Celgene | 2021-10-10 | 2021-10-05 |
Showing 20 of 99. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (23) · Lymphoma (21) · Lymphoma, Non-Hodgkin (19) · Lymphoma, Follicular (17) · Lymphoma, Mantle-Cell (15) · Multiple Myeloma (15) · Hodgkin Disease (13) · Lymphoma, B-Cell (12) · Lymphoma, B-Cell, Marginal Zone (12) · Lymphoma, Large B-Cell, Diffuse (11) · Leukemia (9) · Recurrence (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Waldenstrom Macroglobulinemia (5) · Immune System Diseases (4)
Fate Therapeutics (8) · M.D. Anderson Cancer Center (6) · Fred Hutchinson Cancer Center (5) · Mayo Clinic (4) · Hoffmann-La Roche (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · UNC Lineberger Comprehensive Cancer Center (3) · Aptevo Therapeutics (2) · Celgene (2) · Cephalon (2) · Columbia University (2) · Genentech, Inc. (2) · Incyte Corporation (2) · St. Jude Children's Research Hospital (2) · Wake Forest University Health Sciences (2)
United States (84) · Italy (9) · France (8) · Germany (7) · Spain (6) · Canada (5) · United Kingdom (5) · Australia (4) · Netherlands (4) · Austria (3) · South Korea (3) · Czechia (2) · Hungary (2) · Israel (2) · Poland (2)
Natalie Grover, MD (3) · Rachael Safyan, MD (2) · Scott Stromatt, MD (2) · Adam J Olszewski, MD (1) · Alexey V Danilov, MD (1) · Antonio Pinto, MD (1) · Apostolia M. Tsimberidou, MD, PhD (1) · Armando Santoro, MD (1) · Beth Christian, MD (1)
PMID 19860608, PMID 21816833, PMID 22451423, PMID 23430121, PMID 23843495, PMID 25145344, PMID 25355819, PMID 25769620, PMID 26331432, PMID 26659915, PMID 27442600, PMID 28011903, PMID 29226797, PMID 29276022, PMID 29296805, PMID 29703778, PMID 29908231, PMID 30518502, PMID 31050355, PMID 31190006, PMID 31693429, PMID 31723767, PMID 32126141, PMID 32582591, PMID 32705923, PMID 32770353, PMID 33028076, PMID 33035333, PMID 33334730, PMID 33478921, PMID 33586581, PMID 33598942, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 34749395, PMID 35086141, PMID 35359000, PMID 35460929, PMID 35641232, PMID 35847727, PMID 35852004, PMID 36287231, PMID 36821768, PMID 37981564, PMID 38598516, PMID 38635762, PMID 38843483, PMID 39227452
2015 (3), 2016 (2), P30CA012197 (2), 2008 (1), 2014 (1), 2017 (1), K12CA076930 (1), K12CA120780 (1), P30CA016672 (1), P30CA023108 (1), P30CA138292 (1), P50CA228944 (1), R01CA193140 (1), R01CA247497 (1), U01CA076576 (1)